Refractory Plasma Cell Myeloma
Showing NaN - NaN of 8
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Tocilizumab
- Venetoclax
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 24, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Atlanta, Georgia
- +3 more
Jan 6, 2023
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,
Active, not recruiting
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- ixazomib citrate
- +2 more
-
Scottsdale, Arizona
- +4 more
Mar 28, 2022
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta
Active, not recruiting
- ISS Stage I Plasma Cell Myeloma
- +4 more
- Pembrolizumab
- Radiation Therapy
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Mar 2, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic
Completed
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +115 more
- Fludarabine Phosphate
- +6 more
-
Denver, Colorado
- +10 more
Oct 29, 2019
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (Laboratory Biomarker Analysis,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- Selumetinib
-
Tampa, Florida
- +8 more
Jul 24, 2015